Thomas B

$NWBO For anyone who doubts that paid disinformation campaigns exist to suppress retail sentiment on certain stocks, look no further than @GREEK__G0D and @Tiggersdad2. For a while, I thought maybe they were just bored older guys desperate for engagement or wanting to feel relevance in a sad lonely life. But after today, I’m convinced—these guys are likely paid to undermine stocks like $NWBO and derail any constructive dialogue about its potential. Let’s talk about “Greek God.” He’s claimed multiple times that his sister has glioblastoma. On two occasions he claimed that her neuro-oncologist “smirked” at the mention of DCVax and made a statement that the trial was “flawed” Here’s the problem: the glioblastoma specialist at Capital Health is Dr. Michael Salacz—a listed contributor to the JAMA-published Phase III trial results for DCVax-L. Why would a lead investigator “smirk” at a treatment he publicly helped validate? That’s where the lie slipped. When I called out Greek God on this lie, he backtracked, saying it was a different doctor—but never clarified, then shut the conversation down entirely. That’s not a misunderstanding. That’s deliberate misdirection. Now zoom out. These guys claim to have no financial interest in $NWBO, yet they spend every single day trashing it. A simple scan of their post history and you’ll see that all they do is bash companies they deem “shitcos.” Why? If your sister had GBM, would you dedicate your time to tearing down a company working on the very treatment that could help her? More likely: they’re paid actors, part of a broader campaign to erode trust in vulnerable companies like $NWBO. Whether funded by short interests or PR hit firms, their goal is clear—create confusion, spread doubt, and suppress sentiment. Retail needs to be aware of how subtle and persistent these tactics are. This isn’t organic skepticism—it’s manufactured noise. And it’s time we start calling it out.

Some of those criticisms are fair points, but a number of them are either subjective opinions, incomplete without context, or tied to regulatory timelines that management does not fully control. For example, the “5.5 years with no approval” statement is simply inaccurate. NWBO did not even announce plans for MAA submission until August 2023 and indicated the submission would occur in late 2023. So we are really talking about roughly a 2+ year regulatory review period at most, not 5.5 years. Likewise, “three years from data lock to application” ignores the reality that this was not a standard small molecule drug filing. DCVax-L is a personalized cell therapy/ATMP with an extremely complex CMC and manufacturing component. Building and validating Sawston, aligning with MHRA requirements, implementing the Pediatric Investigation Plan, and preparing a full MAA package for a novel therapy is materially different from filing a traditional biotech application. Whether management could have moved faster is a fair debate, but the timeline alone does not prove incompetence. As for institutional support, collaboration revenue, G&A spend, shareholder communications, etc those are matters of opinion and strategy. Early-stage biotech companies without approved products often struggle with institutional ownership and dilution concerns. Also we have to get you a paid account so you don't have to string post your insightful unbiased content. Do you want me to launch a kickstarter or go fund me?

@PJC3251 @MLariden Three years from Phase 3 data lock to application. 5 1/2 years and no approval. High related party transactions. Poor shareholder communications including hiding the pro forma for the related party acquisition. You can believe in the IP. They’ve made plenty of missteps.

$NWBO you might wanna check out Immunocine. Very exciting stuff! It’s reassuring knowing that there are companies actually moving forward with dendritic cell therapies and doing it the right way!

I have consistently said that, assuming a near term MHRA approval of NWBO’s MAA and no material increase in the current outstanding share count, I believe the stock could reasonably move into the ~$0.60 range shortly after approval. My reasoning is fairly straightforward: if the Sawston facility initially supports approximately 500 patients annually at an estimated revenue of $200k per patient, that would equate to roughly $100 million in annual gross revenue capacity out of the gate. Applying a 10x revenue multiple is how I arrive at that valuation framework. Obviously, there are many variables involved manufacturing scale-up, reimbursement, broader regulatory approvals, partnerships, and execution but as an initial post-approval valuation benchmark, that has been my working assumption. That said, I would be more than happy to be wrong and watch it move well north of $1.

Time to put a price target on $NWBO. I am in at 20c. With MHRA approval for DC-VAX anything is possible, so this is a real thumb-suck, but $2.00 does not seem unreasonable.

@Kelly712717541 You should be able to email George Zavoico, NWBO investor relations to request confirmation

$nwbo. Can someone confirm?

Clown? Have you seen Dr GZs bio? If you think he is a clown, I would hate to think what you would consider a lowly blue collar worker such as myself…. I’ve spoken to George, he is more forthcoming with his opinion than Dave but he qualifies that it is his opinion and not official company position. I hope we get approval soon but nobody can predict with certainty, not even the MHRA themselves.

@YYDSxjm And you believe that clown? Dr. Askhan once said in one of his conferences that approval in a couple of months. And we are still waiting for it to happen. So, what makes you think GZ has more credibility than the Dr. who was wrong about the approval? $NWBO

$NWBO

Hey @MHRAgovuk Tomorrow is my birthday, how about we just go ahead and grant MAA approval to $NWBO DCvaxL. If you haven’t rejected at this point, I’m sure we can figure out how to address open items post approval. Excellent safety profile + statistically meaningful improvement = No Brainer

@ajw02360 @SnackBioTech You are certainly no cheerleader but on this we are aligned.

@SnackBioTech Like I stated a week or so ago, you sure do spend a lot of time and energy on this .20 OTCB ticker. If you had no worries, you wouldn’t even be posting about $NWBO. Something has you bothered for sure. I am not a cheerleader for NW, but I know motives when I see them.

lol. $NWBO

The only one lecturing is you. An investor being excited about a potential milestone shouldn’t trigger you. The tones of my post are always speculative and usually tie into something related to MHRA or comms directly from the company such as the original post here that you decided to engage with. Look at my post history, I’ve posted 5 times this year about $NWBO and we are almost in May so I’m posting once a month which shouldn’t trigger a meltdown like this. Sounds like you need a break from that dangerous job of yours….

@PJC3251 I do one of the most difficult and dangerous jobs in the world, every single day, sometime weeks on end. Stop lecturing about challenges and risk. I know all about both of them. My point was you are always “bullish af” but none of your thoughts or speculation have ever come true.

$nwbo Still going thru 10-k but found the paragraph on third party secondary manufacturing site interesting. Seems to indicate management feels they may need additional production capacity in the near term which feels bullish af.

Actually I’ve been that way since 2020. Guess I’m an idiot….. I will always root for this company because I firmly believe the science behind it and think it will bring a meaningful impact to the treatment of Glioblastoma and possibly other tumor based cancers. It’s easier to tear apart than support something especially when faced with the challenges and delays and risk involved with something difficult. I guess we know which side of the fence you stand…..

@PJC3251 For the past year, You believe anything said about $NWBO is “bullish af”. But yet here we are at .19

$NWBO borrow rate jumped from 7.7% to 10%. Available shares have dwindled as well. Borrow rates haven’t been this high since last October. Shorts might be thinking approval is coming and looking to close out or just taking advantage to close out at this level. Either way, the popcorn is ready. iborrowdesk.com/report/NWBO

@SmellsDonkey @kshaughnessy2 @olenic34269856 @zsaeed $NWBO has published phase 3 (see link) and awaiting a decision by MHRA (UK) on MAA which would be their first major regulatory approval jamanetwork.com/journals/jamao…

$QNTM The financial media starting to take notice @zsaeed

@Naam_kafi_hai @grok

Hey @grok remove the worst president of the USA !!

@adamfeuerstein @SnackBioTech Obvious rejection? LMAO Wake me up when one of your predictions concerning this company comes to fruition

@SnackBioTech Pretty much confirms the $NWBO Advent “merger” was just another delay tactic and distraction from the obvious UK rejection of DCVax. Unfortunately, SEC Enforcement has been neutered.

$NWBO 10K delayed indefinitely. Disappointing. I was hoping for some laughs tonight.

Remember this article from May 10 2022 that coincided with baiting orders that have been accepted in the alleged complaint. This article predicted failure of the company, treatment and trial. Fast forward 4 years and NWBO is on the verge of its first regulatory approval. I guess Adam’s take isn’t always the right take…. statnews.com/2022/05/10/it-…

It’s idiotic comments like this that make me realize you are probably a retired fast food worker that never spent a day in finance. Someone mentions spoofing, you get triggered and try to attack them into silence. If you had actually read the legal documents you’d realize the date I mentioned above was specifically cited as a date the court recognized as having baiting orders in the “amended complaint” that was accepted by the court. It’s sad and pathetic that you don’t understand that baiting orders are a form of spoofing which is so ironic coming from someone claiming to be an authority on market mechanics. Your friends are going to be disappointed how lazy and incompetent you are becoming in defending against any spoofing claims

@PJC3251 @scooterd_speaks @scott_jenn63528 🤣🤣🤣 That wasn’t spoofing on May 10th. That was professional biotech investors having a different opinion than you. If you actually understood what spoofing is you’d recognize how ridiculous you sound.

$NWBO LP ready 900m shares, and sold advent to nwbo(added value to nwbo) . I hope $10+ is the price of BP buy in. MRK acquired TERN with 6.7B, and Trial phase: Phase 1/2 (CARDINAL study) only. So Nwbo's valuation could be $30B after MHRA approval ?

May 10 2022 was the most obvious spoofing event following this article being published by the corrupt shithead Adam Feuerstein. I also think something similar happened last April following another hit piece article by Galzus Research. The timing was comically obvious. On this point we are aligned. We just have different thoughts on valuation and that is fine. For what it’s worth I would prefer that you are correct on price but I won’t be disappointed or surprised if it’s a gradual climb to $10 rather than an overnight event. Cheers! statnews.com/2022/05/10/it-…

@PJC3251 @scott_jenn63528 If we are on the same team, then you should know better. Four years ago when the stock was illegally spoofed down from 2.50 to .40 is where the evaluation should begin . With all the positive news and catalysts we have gotten since then(too many to count) we should be at $10.

Buyout valuation is a different conversation and would be a higher valuation. I’m talking about Day 1 Post MHRA valuation metrics based on expected revenue. Apples and Oranges…. Although I would for all of you that promote ideas of a higher valuation to be correct but for my personal investment I like to stay based in realistic expectations

@PJC3251 @scott_jenn63528 Stop, Number 1 Eden automation will fix those numbers, Juno a few years ago was bought for 9 billion with almost zero revenue. Kite for 11 billion with 500 million . Those were both shitty therapies next to Dcvax L.

Much higher at what point? Certainly down the road with an increase in current production capacity and additional regulatory approvals in other countries, we could expect bigger numbers but I am a realist. I am also an investor that has actually talked to both Dave Innes and George Zavoico over the last two years. Current capacity at Sawston is somewhere between 400-500 patients annually . Let’s assume NICE approves $200k treatment cost. That means at best initial revenue is 100 million. Let’s even blow past a conservative multiplier of 10 X and apply a 20 X which means we are a 2 billion market cap Don’t believe me? Reach out to George and ask him what current capacity at Sawston is

@PJC3251 @scott_jenn63528 Much, much higher, but you most know that, if you are an actual investor